Roche and Pharmasset team to develop hepatitis C drug

Share this article:
Roche and Pharmasset have formed a partnership to develop a
new drug for the treatment of hepatitis C.
Pharmasset will receive an upfront fee, research and development support, and milestone payments that could total $168 million for PSI-6130, the nucleoside polymerase inhibitor that is the lead compound of the partnership. In addition, Pharmasset will receive royalties on product sales and retain certain copromotion
rights in the U.S.
Under the terms of the agreement, Roche will gain worldwide rights,
excluding Latin America and Korea, to PSI-6130. Roche will also receive options to related nucleoside polymerase inhibitors, which, if exercised, could result in Pharmasset receiving in excess of $300 million in total milestones under the agreement.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.